Raloxifene News and Research

RSS

Raloxifene is an oral selective estrogen receptor modulator (SERM) that has oestrogenic actions on bone and anti-oestrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women.

Anastrozole efficacy in breast cancer prevention for high-risk women linked to estrogen levels

Study examines the efficacy of anastrozole in preventing breast cancer in postmenopausal women at high risk, focusing on the role of baseline estradiol levels and their impact on treatment outcomes.

7 Dec 2023

The metabolic effects of endocrine therapy on diabetes mellitus in breast cancer survivors

Researchers discuss the history of endocrine therapies, highlights their adverse metabolic effects, and emphasizes the need for better biomarkers of diabetes.

5 Oct 2023

World-renowned menopause experts summarize the state of menopause knowledge and advocate for further research

In a recent review published in Cell, a group of authors delved into the complexities of menopause, assessed its global impacts on health, and evaluated the effectiveness and safety of current treatments, emphasizing the importance of further research.

6 Sep 2023

Mark Cuban's Cost Plus Drug Company projects huge savings over Medicare for generic cancer medications

Researchers reveal significant cost savings when generic oncology drugs are purchased through the Mark Cuban Cost Plus Drug Company.

13 Jun 2023

Researchers report novel interactions between the SARS-CoV-2 S protein and estrogen receptor alpha

Researchers profiled the binding sites of the entire SARS-CoV-2 spike protein sequence.

26 May 2022

Hormonal therapies for breast and prostate cancers increase the risk of heart attack, stroke

The hormonal therapies used to treat many breast and prostate cancers raise the risk of a heart attack and stroke, and patients should be monitored regularly and receive treatment to reduce risk and detect problems as they occur.

26 Apr 2021

Study: Women at high risk of breast cancer face financial barriers to care

Women at high risk of breast cancer face cost-associated barriers to care even when they have health insurance, a new study has found.

21 Apr 2021

ACR’s updated guideline provides recommendations on treatment of glucocorticoid-induced osteoporosis

The American College of Rheumatology's updated clinical guideline for the prevention and treatment of glucocorticoid-induced osteoporosis is now available online.

7 Jun 2017

Bioinformatics helps identify new, untested drug combinations for treatment of breast cancer

Based on the study of cell signalling networks, the cell signals that drugs alter when they reach their target molecule, an exhaustive in silico analysis of the pairing of 64 therapeutic agents used to treat breast cancer (half already in use and the other half in clinical testing phase) has allowed researchers at the Institute for Research in Biomedicine to identify 10 new and previously untested combinations that hold potential for the treatment of breast cancer.

20 Dec 2016

New guidelines recommend evaluation of osteoporosis risk for all postmenopausal women

Osteoporosis is preventable and treatable, but only a small proportion of people at risk for fractures are evaluated and treated, according to new osteoporosis guidelines written by an expert panel headed by Loyola Medicine endocrinologist Pauline M. Camacho, MD, FACE.

30 Nov 2016

Omega-3 fatty acids can lower risk of breast cancer in postmenopausal obese women

Omega-3 fatty acids may lower the risk of breast cancer in postmenopausal obese women, according to researchers.

24 Feb 2016

Estrogen may protect women against flu

The female sex hormone estrogen has anti-viral effects against the influenza A virus, commonly known as the flu, a new study in American Journal of Physiology—Lung Cellular and Molecular Physiology reports.

13 Jan 2016

Aspirin does not improve survival among breast cancer patients with aggressive disease

Whether aspirin may help prevent or reduce the risk of breast cancer remains a hotly debated research question. While past studies have indicated a potential benefit, most recently in hormone receptor-positive breast cancers, one new study from Penn Medicine suggests otherwise.

9 Dec 2015

Estrogen-like drug may not be beneficial to women with Alzheimer's dementia

An estrogen-like drug, raloxifene, has no demonstrated benefit on memory and thinking skills for women with dementia due to Alzheimer's disease, according to a study published in the November 4, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

5 Nov 2015

UT Southwestern announces launch of new health initiative

UT Southwestern Medical Center today announced the launch of "Call Out Cancer," a new health initiative designed to promote awareness, early detection, and prevention of all types of cancer.

6 Oct 2015

Researchers refine breast cancer risk model to give more accurate assessment

A national risk model that gauges a woman's chance of developing breast cancer has been refined to give a more accurate assessment. The revised figures, based on data from more than one million patients, reveal a 300 percent increase in a subset of women whose five-year risk is estimated at 3 percent or higher.

19 Aug 2015

$Raloxifene: FDA approved treatment for decreasing fracture risk in osteoporosis$

Raloxifene: FDA approved treatment for decreasing fracture risk in osteoporosis

Raloxifene is a U.S. Food and Drug Administration (FDA)-approved treatment for decreasing fracture risk in osteoporosis.

30 Aug 2014

Research suggests effective role for natural steroid hormones in treating breast cancer

A new study supports a growing body of research suggesting a safe and effective role for natural steroid hormones in treating postmenopausal breast cancer, with fewer detrimental side effects and improved health profile than with standard anti-hormone therapies.

24 Jul 2014

Experts join MD Anderson to end cancer

The University of Texas MD Anderson Cancer Center is pleased to announce that one of the world's preeminent experts in breast cancer research and treatment, V. Craig Jordan, Ph.D., will join the institution's efforts to end cancer. Jordan is considered the "Father of Tamoxifen," the groundbreaking therapeutic drug that has saved countless lives.

22 Jul 2014

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

The basic idea of cancer chemoprevention is to arrest or reverse the progression of premalignant cells towards full malignancy, using physiological mechanisms that do not kill healthy cells.

16 Jul 2014